April 28, 2010 (FinancialWire) — AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) has appointed Gary J. Zieziula as executive vice president and chief commercial officer.

In this newly created position, Zieziula will be responsible for the company’s commercial organization including sales, managed markets and reimbursement, marketing, market research, commercial analytics, and sales operations.

He will lead the company’s global commercial strategy in support of the planned label expansion for its Feraheme Injection for intravenous use across all therapeutic indications and imaging applications and evaluate the commercial attractiveness of potential in-licensing opportunities.

Zieziula most recently served as the managing director for pharmaceuticals for Roche S.A. in Greece. Since joining Roche in 2001, he has held several sales and marketing positions, including head of commercial operations, specialty care at Roche USA, where he was responsible for oncology, transplant, anti-infectives and antivirals/HIV products.

Massachusetts-based AMAG Pharmaceuticals is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

On June 30, 2009, AMAG received approval from the U.S. Food and Drug Administration to market Feraheme Injection for intravenous use for the treatment of iron deficiency anemia in adult chronic kidney disease patients.

Streaming Research for all companies mentioned in FinancialWire(tm) news is available via the Investrend Research Syndicate, courtesy of Stock Smart (at http://investrend.stocksmart.com/ss/html/hpcompany.html).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website (http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[hlmsmlh] [clvloy] [biomedphrm]

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.